Sensorion Receives FDA Investigational New Drug Clearance for Arazasetron (SENS-401)
MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced today that it has received the Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with SENS-401, based on…
Read More
Sensorion Announces Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs for Hearing Loss
MONTPELLIER, FRANCE — French biotech firm Sensorion has announced the signature of a research partnership framework agreement with Institut Pasteur (Paris) granting to Sensorion an option to obtain exclusive licenses to develop and market drug candidates in gene therapy coming from collaborative projects, for the restoration, treatment and prevention of hearing disorders. In accordance with…
Read More
Rinri Therapeutics Secures $1.8M Seed Funding to Advance Novel Hearing Regeneration Therapy
SHEFFIELD, UNITED KINGDOM — Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, announced today that it successfully secured £1.4 million (approximately $1.8M USD) in seed funding. The financing, which was co-led by Boehringer Ingelheim Venture Fund and UCB Ventures and joined by BioCity, will support the ongoing growth of the…
Read More
Frequency Therapeutics Announces Positive Phase 1/2 Trial Results for Hearing Restoration Drug
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical…
Read More
Decibel Therapeutics Appoints New Chief Medical Officer and COO
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…
Read MorePharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics
Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…
Read More
Frequency Therapeutics Completes $42 Million Series B Financing
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…
Read More
Sound Pharmaceuticals Advances Phase 2 Clinical Trial in Cystic Fibrosis Patients to Prevent Hearing Loss
SEATTLE, WASHINGTON AND CHARLESTON, SOUTH CAROLINA — Sound Pharmaceuticals, a Seattle-based biotech firm, announced that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with the company’s oral drug, SPI-1005, is aimed to prevent and treat ototoxicity in patients with Cystic Fibrosis undergoing intravenous (IV) tobramycin for the…
Read More
Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…
Read More
Spiral Therapuetics Receives $3.7M Investment to Advance Treatment of Hearing Loss and Inner Ear Disorders
SAN FRANCISCO, CALIFORNIA — According to a news report out this week, early-stage pharmaceutical company Spiral Therapeutics has received a $3.7 million investment towards the development of treatments for hearing loss and other inner ear related disorders. The Series A funding round was led by Camden Partners Nexus, a biomedical-focused venture fund, and Savoir Capital. Spiral Therapeutics’ initial…
Read More